Clinical Trial Update: Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating uproleselan (GMI-1271) in combination with chemotherapy for relapsed/refractory acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Uproleselan (GMI-1271) (uproleselan)

Snippet

Sponsor: GlycoMimetics Incorporated | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: TERMINATED